A Trial of MitoQ for the Treatment of People With Parkinson's Disease
Launched by ANTIPODEAN PHARMACEUTICALS, INC. · May 22, 2006
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Informed consent
- • 2. 30 yrs or older
- • 3. Diagnosis of PD (2 or more of bradykinesia; rest tremor, rigidity)
- • 4. Adequate contraceptive measures (females)
- Exclusion Criteria:
- • 1. Malignancy within last 2 years
- • 2. Pregnancy \& breast-feeding
- • 3. Treatment with any anti-PD drugs within 30 days of enrolment
- • 4. Prior treatment with anti-PD medication exceeding 42 days in total
- • 5. Medication-induced PD/PD not of idiopathic origin
- • 6. CoQ10/idebenone doses of 300mg/day or higher within 120 days, \>25mg/day within 7 days of enrolment
- • 7. Methylphenidate HCl, neuroleptics, reserpine, amphetamines, selegeline or MAOIs within 6 months of enrolment
- • 8. CNS medications at unstable doses within 60 days of enrolment
- • 9. Dietary supplements \> 5 x RDI
- • 10. Hypersensitivity to CoQ10, idebenone or any components of the study drug
- • 11. Unable to swallow
- • 12. Diseases with features of PD
- • 13. Seizure(s) within 12 months prior to enrolment
- • 14. UPDRS tremor score of 4
- • 15. Hamilton Depression Rating Scale score \> 10
- • 16. History of stroke
- • 17. Requirement for dopaminergic drugs
- • 18. Modified Hoehn \& Yahr score \> 2.5
- • 19. History of brain surgery for Parkinson's disease
- • 20. History of structural brain disease / congenital brain abnormality
- • 21. History of ECT
- • 22. Any other clinically significant medical or psychiatric condition or lab abnormality
- • 23. Enrolment in any other pharmacological study within 30 days of enrolment
About Antipodean Pharmaceuticals, Inc.
Antipodean Pharmaceuticals, Inc. is a forward-thinking biopharmaceutical company dedicated to the development and commercialization of innovative therapies aimed at addressing unmet medical needs across various therapeutic areas. With a strong focus on research and development, Antipodean Pharmaceuticals leverages cutting-edge science and advanced technology to create novel drug candidates that enhance patient outcomes. Committed to maintaining the highest ethical standards and regulatory compliance, the company collaborates with healthcare professionals and research institutions to ensure robust clinical trial methodologies and rigorous data analysis, ultimately striving to improve global health through transformative pharmaceutical solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Palmerston North, , New Zealand
Hamilton, , New Zealand
Auckland, , New Zealand
Sydney, New South Wales, Australia
Brisbane, Queensland, Australia
Melbourne, Victoria, Australia
Dunedin, Otago, New Zealand
Christchurch, , New Zealand
Hastings, , New Zealand
Nelson, , New Zealand
Tauranga, , New Zealand
Wellington, , New Zealand
Whangarei, , New Zealand
Patients applied
Trial Officials
Barry J Snow, MD
Principal Investigator
Auckland District Health Board, New Zealand
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials